Therapies and therapeutic approaches in Congenital Disorders of Glycosylation

Glycoconjugate Journal

Volumn 30, Issue 1, 2013, Pages 77-84

  Thiel, Christian ^a   Körner, Christian ^a  

^a Center for Metabolic Diseases Heidelberg   (Germany)

Author keywords

Congenital Disorders of Glycosylation; Glycosylation deficiency; N glycosylation; O glycosylation; Therapeutic approaches; Therapy

Indexed keywords

4 PHENYLBUTYRIC ACID; CARRIER PROTEIN; DOLICHOL PHOSPHATE MANNOSE; ESSENTIAL FATTY ACID; FUCOSE; GUANOSINE DIPHOSPHATE FUCOSE TRANSPORTER; GUANOSINE DIPHOSPHATE MANNOSE; MANNOSE; MANNOSE 6 PHOSPHATE; MANNOSE PHOSPHATE ISOMERASE; METFORMIN; UNCLASSIFIED DRUG;

ARTICLE; CARBOHYDRATE SYNTHESIS; CENTRAL NERVOUS SYSTEM DISEASE; CONGENITAL DISORDER OF GLYCOSYLATION; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1A; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1B; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1H; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 2C; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FATALITY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; LIVER DYSFUNCTION; LOW FAT DIET; NONHUMAN; PHOSPHATIDYLINOSITOL GLYCAN BIOSYNTHESIS CLASS M PROTEIN DEFICIENCY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RECOMMENDED DRUG DOSE; SUPPLEMENTATION;

CARBOHYDRATE METABOLISM, INBORN ERRORS; CONGENITAL DISORDERS OF GLYCOSYLATION; DIET THERAPY; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MALE; MANNOSE; POLYSACCHARIDES;

EID: 84872688257     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-012-9447-5     Document Type: Article

References (61)

1. Dube, D.H., Bertozzi, C.R.: Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4, 477-488 (2005)
2. Moskal, J.R., Kroes, R.A., Dawson, G.: The glycobiology of brain tumors: disease relevance and therapeutic potential. Expert Rev. Neurother. 9, 1529-1545 (2009)
3. Schachter, H., Freeze, H.H.: Glycosylation diseases: quo vadis? Biochim. Biophys. Acta 1792, 925-930 (2009)
4. Jaeken, J.: Congenital disorders of glycosylation (CDG): it's (nearly) all in it! J. Inherit. Metab. Dis. 34, 853-858 (2011)
5. Theodore, M., Morava, E.: Congenital disorders of glycosylation: sweet news. Curr. Opin. Pediatr. 23, 581-587 (2011)
6. Bertini, E., D'Amico, A., Gualandi, F., Petrini, S.: Congenital muscular dystrophies: A brief review. Semin. Pediatr. Neurol. 18, 277-288 (2011)
7. Jaeken, J.: Congenital disorders of glycosylation. Ann. NY Acad. Sci. 1214, 190-198 (2010)
8. Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H.G., Zimmer, K.P., Wu, R., Harms, E., Reiter, K., von Figura, K., Freeze, H.H., Harms, H.K., Marquardt, T.: Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J. Clin. Invest. 101, 1414-1420 (1998)
9. Haeuptle, M.A., Hennet, T.: Congenital disorders of glycosylation: An update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum. Mutat. 30, 1628-1641 (2009)
10. de Lonlay, P., Seta, N.: The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochim. Biophys. Acta 1792, 841-843 (2009)
11. Mention, K., Lacaille, F., Valayannopoulos, V., Romano, S., Kuster, A., Cretz, M., Zaidan, H., Galmiche, L., Jaubert, F., de Keyzer, Y., Seta, N., de Lonlay, P.: Development of liver disease despite mannose treatment in two patients with CDG-Ib. Mol. Genet. Metab. 93, 40-43 (2008)
12. Alton, G., Kjaergaard, S., Etchison, J.R., Skovby, F., Freeze, H.H.: Oral ingestion of mannose elevates blood mannose levels: A first step toward a potential therapy for carbohydrate-deficient glycoprotein syndrome type I. Biochem. Mol. Med. 60, 127-133 (1997)
13. Wood, F.C., Cahill, G.F.: Mannose utilization in man. J. Clin. Invest. 42, 1300-1312 (1963)
14. DeRossi, C., Bode, L., Eklund, E.A., Zhang, F., Davis, J.A., Westphal, V., Wang, L., Borowsky, A.D., Freeze, H.H.: Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality. J. Biol. Chem. 281, 5916-5927 (2006)
15. Sols, A., Cadenas, E., Alvarado, F.: Enzymatic basis of mannose toxicity in honey bees. Science 131, 297-298 (1960)
16. de la Fuente, M., Peñas, P.F., Sols, A.: Mechanism of mannose toxicity. Biochem. Biophys. Res. Commun. 140, 51-55 (1986)
17. Harms, H.K., Zimmer, K.P., Kurnik, K., Bertele-Harms, R.M., Weidinger, S., Reiter, K.: Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr. 91, 1065-1072 (2002)
18. Schroeder, A.S., Kappler, M., Bonfert, M., Borggraefe, I., Schoen, C., Reiter, K.: Seizures and stupor during intravenous mannose therapy in a patient with CDG syndrome type 1b (MPI-CDG). J. Inherit. Metab. Dis. (2011). doi: 10.1007/s10545-010-9252-x
19. Liem, Y.S., Bode, L., Freeze, H.H., Leebeek, F.W., Zandbergen, A.A., Paul Wilson, J.: Using heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 220-224 (2008)
20. Etzioni, A., Frydman, M., Pollack, S., Avidor, I., Phillips, M.L., Paulson, J.C., Gershoni-Baruch, R.: Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N. Engl. J. Med. 327, 1789-1792 (1992)
21. Lübke, T., Marquardt, T., Etzioni, A., Hartmann, E., von Figura, K., Körner, C.: Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat. Genet. 28, 73-76 (2001)
22. Lühn, K., Wild, M.K., Eckhardt, M., Gerardy-Schahn, R., Vestweber, D.: The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat. Genet. 28, 69-72 (2001)
23. Lübke, T., Marquardt, T., von Figura, K., Körner, C.: A new type of carbohydrate-deficient glycoprotein syndrome due to a decreased import of GDP-fucose into the golgi. J. Biol. Chem. 274, 25986-25989 (1999)
24. Marquardt, T., Brune, T., Lühn, K., Zimmer, K.P., Körner, C., Fabritz, L., van der Werft, N., Vormoor, J., Freeze, H.H., Louwen, F., Biermann, B., Harms, E., von Figura, K., Vestweber, D., Koch, H.G.: Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J. Pediatr. 134, 681-688 (1999)
25. Etzioni, A., Tonetti, M.: Fucose supplementation in leukocyte adhesion deficiency type II. Blood 95, 3641-3643 (2000)
26. Hidalgo, A., Ma, S., Peired, A.J., Weiss, L.A., Cunningham-Rundles, C., Frenette, P.S.: Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood 101, 1705-1712 (2003)
27. Helmus, Y., Denecke, J., Yakubenia, S., Robinson, P., Lühn, K., Watson, D.L., McGrogan, P.J., Vestweber, D., Marquardt, T., Wild, M.K.: Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood 107, 3959-3966 (2006)
28. Marquardt, T., Lühn, K., Srikrishna, G., Freeze, H.H., Harms, E., Vestweber, D.: Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 94, 3976-3985 (1999)
29. Sturla, L., Puglielli, L., Tonetti, M., Berninsone, P., Hirschberg, C.B., De Flora, A., Etzioni, A.: Impairment of the Golgi GDP-L-fucose transport and unresponsiveness to fucose replacement therapy in LAD II patients. Pediatr. Res. 49, 537-542 (2001)
30. Lühn, K., Marquardt, T., Harms, E., Vestweber, D.: Discontinuation of fucose therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte counts. Blood 97, 330-332 (2001)
31. Wild, M.K., Lühn, K., Marquardt, T., Vestweber, D.: Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs 172, 161-173 (2002)
32. Hidalgo, A., Ma, S., Peired, A.J., Weiss, L.A., Cunningham-Rundles, C., Frenette, P.S.: Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood 101, 1705-1712 (2003)
33. Gazit, Y., Mory, A., Etzioni, A., Frydman, M., Scheuerman, O., Gershoni-Baruch, R., Garty, B.Z.: Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature. J. Clin. Immunol. 30, 308-313 (2010)
34. Chantret, I., Dancourt, J., Dupré, T., Delenda, C., Bucher, S., Vuillaumier-Barrot, S., Ogier de Baulny, H., Peletan, C., Danos, O., Seta, N., Durand, G., Oriol, R., Codogno, P., Moore, S.E.: A deficiency in dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl alpha3-glucosyltransferase defines a new subtype of congenital disorders of glycosylation. J. Biol. Chem. 278, 9962-9971 (2003)
35. Almeida, A.M., Murakami, Y., Layton, D.M., Hillmen, P., Sellick, G.S., Maeda, Y., Richards, S., Patterson, S., Kotsianidis, I., Mollica, L., Crawford, D.H., Baker, A., Ferguson, M., Roberts, I., Houlston, R., Kinoshita, T., Karadimitris, A.: Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nat. Med. 12, 846-851 (2006)
36. Almeida, A.M., Murakami, Y., Baker, A., Maeda, Y., Roberts, I.A., Kinoshita, T., Layton, D.M., Karadimitris, A.: Targeted therapy for inherited GPI deficiency. N. Engl. J. Med. 356, 1641-1647 (2007)
37. Almeida, A., Layton, M., Karadimitris, A.: Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG. Biochim. Biophys. Acta 1792, 874-880 (2009)
38. Panneerselvam, K., Freeze, H.H.: Mannose corrects altered N-glycosylation in carbohydrate deficient glycoprotein syndrome fibroblasts. J. Clin. Invest. 97, 1478-1487 (1996)
39. Körner, C., Lehle, L., von Figura, K.: Carbohydrate- deficient glycoprotein syndrome type 1: correction of the glycosylation defect by deprivation of glucose or supplementation of mannose. Glycoconj. J. 15, 499-505 (1998)
40. Mayatepek, E., Kohlmüller, D.: Mannose supplementation in carbohydrate-deficient glycoprotein syndrome type I and phosphomannomutase deficiency. Eur. J. Pediatr. 157, 605-606 (1998)
41. Kjaergaard, S., Kristiansson, B., Stibler, H., Freeze, H.H., Schwartz, M., Martinsson, T., Skovby, F.: Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr. 87, 884-888 (1998)
42. Mayatepek, E., Schröder, M., Kohlmüller, D., Bieger, W.P., Nützenadel, W.: Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr. 86, 1138-1140 (1997)
43. Rutschow, S., Thiem, J., Kranz, C., Marquardt, T.: Membrane-permeant derivatives of mannose-1-phosphate. Bioorg. Med. Chem. 10, 4043-4049 (2002)
44. Eklund, E.A., Merbouh, N., Ichikawa, M., Nishikawa, A., Clima, J.M., Dorman, J.A., Norberg, T., Freeze, H.H.: Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts. Glycobiology 15, 1084-1093 (2005)
45. Hardré, R., Khaled, A., Willemetz, A., Dupré, T., Moore, S., Gravier-Pelletier, C., Le Merrer, Y.: Mono, di and tri-mannopyranosyl phosphates as mannose-1-phosphate prodrugs for potential CDG-Ia therapy. Bioorg. Med. Chem. Lett. 17, 152-155 (2007)
46. Shang, J., Lehrman, M.A.: Metformin-stimulated mannose transport in dermal fibroblasts. J. Biol. Chem. 279, 9703-9712 (2004)
47. Dahl, R., Bravo, Y., Sharma, V., Ichikawa, M., Dhanya, R.P., Hedrick, M., Brown, B., Rascon, J., Vicchiarelli, M., Mangravita-Novo, A., Yang, L., Stonich, D., Su, Y., Smith, L.H., Sergienko, E., Freeze, H.H., Cosford, N.D.: Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J. Med. Chem. 54, 3661-3668 (2011)
48. Sharma, V., Ichikawa, M., He, P., Bravo, Y., Dahl, R., Ng, B.G., Cosford, N.D., Freeze, H.H.: Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. J. Biol. Chem. 286, 39431-39438 (2011)
49. Thiel, C., Körner, C.: Mouse models for congenital disorders of glycosylation. J. Inherit. Metab. Dis. 34, 879-889 (2011)
50. Muntoni, F., Torelli, S., Wells, D.J., Brown, S.C.: Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies. Curr. Opin. Neurol. 24, 437-442 (2011)
51. Ishikawa, H.O., Higashi, S., Ayukawa, T., Sasamura, T., Kitagawa, M., Harigaya, K., Aoki, K., Ishida, N., Sanai, Y., Matsuno, K.: Notch deficiency implicated in the pathogenesis of congenital disorder of glycosylation IIc. Proc. Natl. Acad. Sci. USA 102, 18532-18537 (2005)
52. Nakamura, N., Lyalin, D., Panin, V.M.: Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes. Semin. Cell Dev. Biol. 21, 622-630 (2010)
53. Thornhill, P., Bassett, D., Lochmüller, H., Bushby, K., Straub, V.: Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). Brain 131, 1551-1561 (2008)
54. Song, Y., Willer, J.R., Scherer, P.C., Panzer, J.A., Kugath, A., Skordalakes, E., Gregg, R.G., Willer, G.B., Balice-Gordon, R.J.: Neural and synaptic defects in slytherin, a zebrafish model for human congenital disorders of glycosylation. PLoS One 5, e13743 (2010)
55. Avsar-Ban, E., Ishikawa, H., Manya, H., Watanabe, M., Akiyama, S., Miyake, H., Endo, T., Tamaru, Y.: Protein O-mannosylation is necessary for normal embryonic development in zebrafish. Glycobiology 20, 1089-1102 (2010)
56. Struwe, W.B., Hughes, B.L., Osborn, D.W., Boudreau, E.D., Shaw, K.M., Warren, C.E.: Modeling a congenital disorder of glycosylation type I in C. elegans: A genome-wide RNAi screen for N-glycosylation-dependent loci. Glycobiology 19, 1554-1562 (2009)
57. Struwe, W.B., Warren, C.E.: High-throughput RNAi screening for N-glycosylation dependent loci in Caenorhabditis elegans. Methods Enzymol. 480, 477-493 (2010)
58. Schneider, A., Thiel, C., Rindermann, J., DeRossi, C., Popovici, D., Hoffmann, G.F., Gröne, H.J., Körner, C.: Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice. Nat. Med. 18, 71-73 (2012)
59. Barresi, R., Michele, D.E., Kanagawa, M., Harper, H.A., Dovico, S.A., Satz, J.S., Moore, S.A., Zhang, W., Schachter, H., Dumanski, J.P., Cohn, R.D., Nishino, I., Campbell, K.P.: LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 10, 696-703 (2004)
60. Kanagawa, M., Nishimoto, A., Chiyonobu, T., Takeda, S., Miyagoe-Suzuki, Y., Wang, F., Fujikake, N., Taniguchi, M., Lu, Z., Tachikawa, M., Nagai, Y., Tashiro, F., Miyazaki, J., Tajima, Y., Takeda, S., Endo, T., Kobayashi, K., Campbell, K.P., Toda, T.: Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum. Mol. Genet. 18, 621-631 (2009)
61. Brockington, M., Torelli, S., Sharp, P.S., Liu, K., Cirak, S., Brown, S.C., Wells, D.J., Muntoni, F.: Transgenic overexpression of LARGE induces α-dystroglycan hyperglycosylation in skeletal and cardiac muscle. PLoS One 5, e14434 (2010)